Synvista Therapeutics (SYNI) Stock Price, News & Analysis

Company Overview

Synvista Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule immunomodulators for the treatment of cancer, inflammatory and autoimmune diseases. The firm’s research strategy centers on identifying novel compounds that can modulate key immune checkpoints and signaling pathways, with the goal of restoring or enhancing immune function in disease settings.

The company’s pipeline comprises multiple discovery‐ and preclinical‐stage candidates designed to target both tumor‐associated immunosuppression and chronic inflammatory processes. Synvista leverages a proprietary medicinal chemistry platform to optimize the potency, selectivity and pharmacokinetic profiles of its lead molecules, and it plans to advance select candidates into early-stage clinical trials as data allow.

Synvista collaborates with academic research centers and contract research organizations in North America and Asia to conduct pharmacology, toxicology and formulation studies. While the company remains in the pre-commercial phase, it aims to establish strategic partnerships to support the further development and potential out-licensing of its immuno‐oncology and anti‐inflammatory programs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 24 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SYNI
• CIK: N/A
• Web: www.synvista.com
• Phone: (201) 934-5000
• Fax: 201-934-8880
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A